Interneuron citicoline NDA for stroke planned for 1997 based on secondary analysis of confirmatory trial.
INTERNEURON CITICOLINE PHASE III STROKE TRIAL SHOWS EFFECT IN SECONDARY ANALYSIS of moderate-to-severe stroke patients, Interneuron CEO Glenn Cooper, MD, told a Montgomery Securities health care conference in New York City July 15. The drug did not show a statistically significant benefit in the primary endpoint of all patients as assessed by the Barthel Index of neurologic function. Cooper maintained that the primary endpoint did not show a benefit because of an unexpectedly high number of patients with mild stroke in the placebo group.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth